Seattle Genetics Inc. (SGEN) announced Monday morning that it was granted Breakthrough Therapy Designation by the FDA for ADCETRIS in the treatment of Frontline Advanced Hodgkin Lymphoma.
from RTT - Before the Bell http://ift.tt/2fNg764
via IFTTT
No comments:
Post a Comment